Iraq has long sought to expand its domestic pharmaceutical manufacturing capacity, both to reduce reliance on imports and to provide more affordable medicines to its population. For investors prepared to commit the time and capital, the framework is workable but the path from project concept to operational facility involves multiple authorities and a sequence of approvals that, while navigable, demands careful planning from the outset. The decisions made in the earliest months of a project, particularly about legal vehicle, location, and product portfolio, materially shape the regulatory journey that follows.
Choosing the Legal Vehicle
The starting point is the choice of legal vehicle and the investment regime under which the project will be developed. Most pharmaceutical manufacturing investors choose a limited liability company under the Iraqi Companies Law No. 21 of 1997, although joint stock companies are sometimes preferred for larger projects with multiple investors, and joint ventures with an Iraqi partner remain common where local expertise or assets are valuable. Pharmaceutical manufacturing is open to foreign ownership, but the chosen structure has implications for governance, profit repatriation, exit strategy, and the suite of approvals that follows.
Many manufacturing projects are structured under the Investment Law No. 13 of 2006 (as amended), which offers tax exemptions, customs facilitations, and land allocation benefits for projects approved by the National Investment Commission or the relevant Provincial Investment Commission. The Investment Law route adds an additional approval at the front of the process, but the incentives, corporate income tax exemption for up to ten years in some provinces, duty-free importation of equipment and raw materials during construction, and preferential access to industrial land typically more than justify the additional procedural step for serious manufacturing projects.
Sequence of Approvals
Once the legal vehicle is established, the project must secure approvals from several authorities, each with its own requirements and timing. The most important of these are:
- National or Provincial Investment Commission, for the investment license under Law No. 13 of 2006
- Ministry of Industry and Minerals, for the industrial license to operate a manufacturing facility
- Ministry of Health (IDCD), for the pharmaceutical manufacturing authorization specifically
- Ministry of Environment, for environmental clearance
- Civil Defense Directorate, for fire safety certification
- Municipal authorities, for building permits and zoning compliance
These approvals run partly in parallel and partly in sequence, and the project’s timeline depends heavily on how well they are managed in combination. Of all of them, the pharmaceutical manufacturing authorization from the Ministry of Health is the most technically demanding.
GMP and Facility Design
To obtain the manufacturing authorization, the facility must comply with Good Manufacturing Practice standards adopted by the Ministry of Health, broadly aligned with WHO GMP guidelines and increasingly with PIC/S standards. GMP compliance is not a single document but a way of operating that touches every aspect of the facility: design, HVAC systems, qualification and validation of equipment, water systems, raw material handling, personnel training, documentation, quality control laboratory operations, and final batch release procedures.
Facility design must reflect the dosage forms intended to be manufactured. Solid oral dosage forms (tablets, capsules) require segregated areas, dust control systems, and unidirectional material and personnel flows. Sterile products demand cleanroom infrastructure, environmental monitoring, and aseptic processing controls of an entirely different order. Hormonal products, cytotoxics, and certain antibiotics particularly beta-lactams, generally require dedicated facilities of their own due to cross-contamination risks, and trying to share infrastructure with other product types is a path that no regulator in the region will accept. These design decisions must be made before the first wall is built and reflected in the layout drawings submitted to the Ministry of Health for site clearance.
Personnel
Each facility must appoint qualified personnel approved by the Ministry of Health. The technical manager is normally a qualified Iraqi pharmacist with adequate experience, and the heads of production, quality control, and quality assurance must be separate individuals with appropriate credentials. Staffing levels, training programs, and the organizational structure connecting these roles all form part of the GMP assessment. Recruitment in this sector is competitive, and one of the more common stumbling blocks for new entrants is securing and retaining a stable team of senior technical staff.
Pre-Licensing Inspection
Once construction is complete and the facility is equipped, the Ministry of Health conducts a pre-licensing GMP inspection. This is typically a multi-day, on-site assessment covering documentation, facility integrity, equipment qualification, validation activities, quality systems, and process simulations. The inspectors classify their findings as critical, major, or minor, and the company must respond with corrective and preventive actions before the GMP certificate is issued. Critical observations almost always have to be resolved before the certificate is issued; major and minor observations follow a defined remediation timeline.
The GMP certificate, once granted, has a defined validity, typically two to three years and is subject to renewal following further inspection. During the validity period, the facility must maintain ongoing compliance and submit major changes (new dosage forms, new equipment, significant modifications) for prior approval. Failure to maintain compliance can result in suspension of the GMP certificate, which in turn affects the registration status of every product manufactured at the site.
Product Registration and Commercial Operation
Even after the facility is licensed, each product manufactured there must be registered separately with the IDCD through the process. The GMP certificate is a prerequisite for those applications. Locally manufactured products may benefit from preferential treatment in KIMADIA tenders and, in certain therapeutic categories, faster registration, which is one of the principal commercial drivers of local manufacturing. They also avoid import logistics and customs duties, reduce foreign currency exposure, and (in projects under the Investment Law) benefit from the available incentives.
Practical Challenges
Prospective investors should weigh these advantages against the real challenges of operating in Iraq: securing reliable utilities, importing specialized equipment and raw materials, managing customs clearance for ongoing supplies, recruiting and retaining qualified technical staff, and navigating a regulatory process that involves multiple agencies with overlapping mandates. Strategic decisions about location (Baghdad, Erbil, Najaf, Basra, and others all have different advantages), scale, product portfolio, and partnerships including joint ventures with established manufacturers, materially affect the project’s success.
How We Can Help
Etihad Law Firm advises domestic and foreign investors throughout the full lifecycle of pharmaceutical manufacturing projects in Iraq from feasibility assessment and entity formation, through investment licensing, GMP preparation and inspection, product registration, and operational compliance. We also represent clients in disputes with regulators, contractors, and partners that arise during construction and operation, and in the structuring of joint ventures and exits.